Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Brian J Platt"'
Publikováno v:
eLife, Vol 9 (2020)
Synaptodendritic pruning is a common cause of cognitive decline in neurological disorders, including HIV-associated neurocognitive disorders (HAND). HAND persists in treated patients as a result of chronic inflammation and low-level expression of vir
Externí odkaz:
https://doaj.org/article/3b5f7f7602cd410bb2d8ece82693d122
Autor:
Chad E. Beyer, Jason M. Dwyer, Michael J. Piesla, Brian J. Platt, Ru Shen, Zia Rahman, Karen Chan, Melissa T. Manners, Tarek A. Samad, Jeffrey D. Kennedy, Brendan Bingham, Garth T. Whiteside
Publikováno v:
Neurobiology of Disease, Vol 39, Iss 2, Pp 148-155 (2010)
Rimonabant was the first clinically marketed cannabinoid (CB)1 receptor antagonist developed to treat obesity. Unfortunately, CB1 receptor antagonism produced adverse psychiatric events in patients. To determine whether this occurs pre-clinically, we
Externí odkaz:
https://doaj.org/article/076a332ba28d4a31822f0239f65decee
Publikováno v:
eLife, Vol 9 (2020)
eLife
eLife
Synaptodendritic pruning is a common cause of cognitive decline in neurological disorders, including HIV-associated neurocognitive disorders (HAND). HAND persists in treated patients as a result of chronic inflammation and low-level expression of vir
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c731ea32239cb23895a8f0fa9ecc286
https://elifesciences.org/articles/49717
https://elifesciences.org/articles/49717
Autor:
Mark R. Bowlby, Jonathan Laird Gross, Li Di, Albert J. Robichaud, Thomas A. Comery, Dahui Zhou, Nicholas J. Brandon, Sze Jean Y, Adedayo Adedoyin, Guoming Zhang, Brian J. Platt
Publikováno v:
Bioorganic & Medicinal Chemistry Letters. 21:5957-5960
On the basis of the previously reported benzimidazole 1,3'-bipyrrolidine benzamides (1), a series of related pyrrolidin-3-yl-N-methylbenzamides were synthesized and evaluated as H(3) receptor antagonists. In particular, compound 32 exhibits potent H(
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28e54558bc89f7f10bdcca6d3eb85521
https://doi.org/10.1016/j.bmcl.2011.07.061
https://doi.org/10.1016/j.bmcl.2011.07.061
Autor:
Brendan Bingham, Garth T. Whiteside, Ru Shen, Melissa T. Manners, Michael J. Piesla, Brian J. Platt, Zia Ur Rahman, Jason M. Dwyer, Tarek A. Samad, Karen Chan, Jeffrey D. Kennedy, Chad E. Beyer
Publikováno v:
Neurobiology of Disease, Vol 39, Iss 2, Pp 148-155 (2010)
Rimonabant was the first clinically marketed cannabinoid (CB)(1) receptor antagonist developed to treat obesity. Unfortunately, CB(1) receptor antagonism produced adverse psychiatric events in patients. To determine whether this occurs pre-clinically
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8bd981d9210a3628205e75af073dd39
https://doi.org/10.1016/j.nbd.2010.03.020
https://doi.org/10.1016/j.nbd.2010.03.020
Autor:
G H Johnston, Eugene John Trybulski, John C. L. Erve, Brian W. Strassle, A. Adedoyin, Jeffrey D. Kennedy, James E. Harrison, Claudine Pulicicchio, Michael J. Piesla, Peimin Lu, Kathryn E. Rogers, Puwen Zhang, Brian J. Platt, Terri Cummons, Garth T. Whiteside, Liza Leventhal, Chad E. Beyer, Zoë A. Hughes, Darlene C. Deecher, L Manzino, Lilly Mark, Jason M. Dwyer
Publikováno v:
British Journal of Pharmacology. 160:1105-1118
Background and purpose: Antidepressants, which raise the CNS concentrations of 5-HT and noradrenaline, are frequently used in the treatment of chronic pain; however, it is not known if increasing CNS noradrenaline levels alone is sufficient for effic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4f60e6b8a1f1b1cc97f891a5bd642c1
https://doi.org/10.1111/j.1476-5381.2010.00690.x
https://doi.org/10.1111/j.1476-5381.2010.00690.x
Autor:
Shen Z, Tom A. Comery, David Smith, Brian J. Platt, Terrance H. Andree, Zhang Minsheng, Magid Abou-Gharbia, Sukoff-Rizzo Sj, Havran Lm, Chong Dc, Natasha Kagan, Zoë A. Hughes, Kelly Sullivan, Bach Ac rd, Boyd L. Harrison, Wayne E. Childers, Magda Asselin, Sharon Rosenzweig-Lipson, Claudine Pulicicchio, Steven M. Grauer, Marathias, George Theodore Grosu, Mark Day, Bicksler Jj, Chad E. Beyer, Adedayo Adedoyin, Christine Huselton, Sabb Al, Suzan Aschmies, Ronald L. Magolda, Warren D. Hirst, Kleintop T, Albert J. Robichaud
Publikováno v:
Journal of Medicinal Chemistry. 53:4066-4084
As part of an effort to identify 5-HT(1A) antagonists that did not possess typical arylalkylamine or keto/amido-alkyl aryl piperazine scaffolds, prototype compound 10a was identified from earlier work in a combined 5-HT(1A) antagonist/SSRI program. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8128f3b71923ae4c75a96a7c24e6d62e
https://doi.org/10.1021/jm1000908
https://doi.org/10.1021/jm1000908
Autor:
Richard J. Murrills, Miles D. Houslay, Sheree F. Logue, May Tam, Cody Kelley, Thomas A. Comery, Steven M. Grauer, Jason M. Dwyer, Julie A. Brennan, Rachel Navarra, Michael J. Agostino, Virginia L. Pulito, Jonathon P. Day, Li-Xin Jiang, Sarah J. Neal, Nicholas J. Brandon, Brian J. Platt, Stacey J. Sukoff Rizzo, Subha Lakkaraju, Xiaotian Zhong, Michy P. Kelly
Publikováno v:
Proceedings of the National Academy of Sciences. 107:8457-8462
Phosphodiesterase 11A (PDE11A) is the most recently identified family of phosphodiesterases (PDEs), the only known enzymes to break down cyclic nucleotides. The tissue expression profile of this dual specificity PDE is controversial, and little is un
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6791ec648280e9a0a701d844a9352cb
https://doi.org/10.1073/pnas.1000730107
https://doi.org/10.1073/pnas.1000730107
Autor:
Mark Robert John, Huai-Ping Ling, Sharon Rosenzweig-Lipson, Sarah J. Neal, Jason M. Dwyer, Qian Lin, Bin Luo, Chad E. Beyer, Lee E. Schechter, Brian J. Platt
Publikováno v:
Psychopharmacology. 209:303-311
The effects of angiotensin (Ang) IV result from binding to a constitutively active metallopeptidase known as the AT(4) receptor (or oxytocinase/insulin-regulated membrane aminopeptidase). While in vitro evidence indicates that Ang IV inhibits the pep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5dd26b26cc38f08edf6dacb77675c63
https://doi.org/10.1007/s00213-010-1791-1
https://doi.org/10.1007/s00213-010-1791-1